ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

[News]

ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.

More... (http://www.news-medical.net/news/20111207/ZIOPHARM-receives-European-patent-allowance-for-palifosfamide-to-treat-cancer.aspx)